The FDA has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and only subcutaneous, chemo-free treatment for patients with EGFR-mutated non-small cell lung cancer across all ...

Older adults living with heart failure with preserved ejection fraction (HFpEF) are frequently labeled as having chronic ...

A groundbreaking phase 2 clinical trial has unveiled promising advancements in the treatment landscape for non-small cell lung cancer (NSCLC), ...

Improved Pharma, a leader in pharmaceutical research and solid-state chemistry, is pleased to announce a significant upgrade ...

Chris Draft said patients with lung cancer and their caregivers can regain control after diagnosis by showing up, staying ...

Acumatica development and service provider Sprinterra has recognized Cavallo, the leader in AI-powered Profit Maximization, for its strong integration with Acumatica ? reinforcing Cavallo's role as a ...

Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious ...

As smoking rates fall, lung cancer in never-smokers (LCINS) represents an increasing share of lung cancer diagnoses. These cancers are frequently ...

The FDA accepted the New Drug Application for zanzalintinib plus atezolizumab for the treatment of adult patients with metastatic colorectal cancer.

NSCLC Market Insights report includes a comprehensive understanding of current treatment practices, EGFR-NSCLC emerging drugs, market share of individual therapies, and current and forecasted market ...

The FDA has granted regenerative medicine advanced therapy (RMAT) designation to KB707 for the treatment of advanced or metastatic NSCLC. 1 KB707 is an inhaled, re-dosable immunotherapy designed to ...